Application Of Hydroxypropyl Betadex In Everolimus Tablets

Everolimus is an inhibitor of mTOR, a serine threonine kinase downstream of the PI3K/AKT pathway. Ivemus was first developed by Swiss Novartis. The trade name Certican was first listed in Sweden in 2003 and has fully occupied the European market in 2006. The FDA approved its use for sunitinib or sorafenib in patients with advanced kidney cancer failure. According to Novartis, everolimus can slow the growth of kidney cancer cells and reduce mortality by 67%.

Everolimus, Hydroxypropyl Betadex, and deoxycholic acid were dissolved in absolute ethanol and then made into tablets. Compared with the prior art, the preparation process of the invention is simple, the drug dispersion is uniform, the production process is smooth, and the drug dissolves quickly.